new COX-2 inhibitor called Bextra (valdecoxib)
You'll see a new COX-2 inhibitor called Bextra (valdecoxib).
It'll be co-marketed by Pharmacia and Pfizer...the same companies that market Celebrex (celecoxib).
Bextra is approved for osteoarthritis...rheumatoid arthritis...and dysmenorrhea. It's NOT approved yet for acute pain...but that's likely to change after the company submits additional studies to the FDA.
Get concise, unbiased advice for effective drug therapy, plus CE/CME
Prescriber Insights: APRN includes:
- Cutting-edge advice about new medications and how they fit into practice
- Unbiased, evidence-based, 100% free of financial support from the pharma industry written by your peers
- Side-by-side comparisons of drugs by class or disease state, plus FAQs, pros/cons, and simple recommendations
Already a subscriber? Log in
Volume pricing available. Get a quote